Nathalie L Albert1,2,3, M Unterrainer4, D F Fleischmann5,6, S Lindner4, F Vettermann4, A Brunegraf4, L Vomacka4, M Brendel4, V Wenter4, C Wetzel7, R Rupprecht7, J-C Tonn5,8, C Belka5,6, P Bartenstein4,5,9, M Niyazi5,6. 1. Department of Nuclear Medicine, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. Nathalie.Albert@med.uni-muenchen.de. 2. German Cancer Consortium (DKTK), partner site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany. Nathalie.Albert@med.uni-muenchen.de. 3. "Munich Cluster of Systems Neurology (SyNergy)", Munich, Germany. Nathalie.Albert@med.uni-muenchen.de. 4. Department of Nuclear Medicine, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. 5. German Cancer Consortium (DKTK), partner site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany. 6. Department of Radiation Oncology, LMU Munich, Munich, Germany. 7. Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany. 8. Department of Neurosurgery, LMU Munich, Munich, Germany. 9. "Munich Cluster of Systems Neurology (SyNergy)", Munich, Germany.
Abstract
OBJECTIVE: The 18-kDa mitochondrial translocator protein (TSPO) was reported to be upregulated in gliomas. 18F-GE-180 is a novel 3rd generation TSPO receptor ligand with improved target-to-background contrast compared to previous tracers. In this pilot study, we compared PET imaging with 18F-GE-180 and MRI of patients with untreated and recurrent pretreated glioblastoma. METHODS: Eleven patients with histologically confirmed IDH wildtype gliomas (10 glioblastomas, 1 anaplastic astrocytoma) underwent 18F-GE-180 PET at initial diagnosis or recurrence. The PET parameters mean background uptake (SUVBG), maximal tumour-to-background ratio (TBRmax) and PET volume using different thresholds (SUVBG × 1.6, 1.8 and 2.0) were evaluated in the 60-80 min p.i. summation images. The different PET volumes were compared to the contrast-enhancing tumour volume on MRI. RESULTS: All gliomas were positive on 18F-GE-180 PET and were depicted with extraordinarily high tumour-to-background contrast (median SUVBG 0.47 (0.37-0.93), TBRmax 6.61 (3.88-9.07)). 18F-GE-180 uptake could be found even in areas without contrast enhancement on MRI, leading to significantly larger PET volumes than MRI-based volumes (median 90.5, 74.5, and 63.8 mL vs. 31.0 mL; p = 0.003, 0.004, 0.013). In percentage difference, the PET volumes were on average 179%, 135%, and 90% larger than the respective MRI volumes. The median spatial volumetric correlation (Sørensen-Dice coefficient) of PET volumes and MRI volumes prior to radiotherapy was 0.48, 0.54, and 0.58. CONCLUSION: 18F-GE-180 PET provides a remarkably high tumour-to-background contrast in untreated and pretreated glioblastoma and shows tracer uptake even beyond contrast enhancement on MRI. To what extent 18F-GE-180 uptake reflects the tumour extent of human gliomas and inflammatory cells remains to be evaluated in future prospective studies with guided stereotactic biopsies and correlation of histopathological results.
OBJECTIVE: The 18-kDa mitochondrial translocator protein (TSPO) was reported to be upregulated in gliomas. 18F-GE-180 is a novel 3rd generation TSPO receptor ligand with improved target-to-background contrast compared to previous tracers. In this pilot study, we compared PET imaging with 18F-GE-180 and MRI of patients with untreated and recurrent pretreated glioblastoma. METHODS: Eleven patients with histologically confirmed IDH wildtype gliomas (10 glioblastomas, 1 anaplastic astrocytoma) underwent 18F-GE-180 PET at initial diagnosis or recurrence. The PET parameters mean background uptake (SUVBG), maximal tumour-to-background ratio (TBRmax) and PET volume using different thresholds (SUVBG × 1.6, 1.8 and 2.0) were evaluated in the 60-80 min p.i. summation images. The different PET volumes were compared to the contrast-enhancing tumour volume on MRI. RESULTS: All gliomas were positive on 18F-GE-180 PET and were depicted with extraordinarily high tumour-to-background contrast (median SUVBG 0.47 (0.37-0.93), TBRmax 6.61 (3.88-9.07)). 18F-GE-180 uptake could be found even in areas without contrast enhancement on MRI, leading to significantly larger PET volumes than MRI-based volumes (median 90.5, 74.5, and 63.8 mL vs. 31.0 mL; p = 0.003, 0.004, 0.013). In percentage difference, the PET volumes were on average 179%, 135%, and 90% larger than the respective MRI volumes. The median spatial volumetric correlation (Sørensen-Dice coefficient) of PET volumes and MRI volumes prior to radiotherapy was 0.48, 0.54, and 0.58. CONCLUSION: 18F-GE-180 PET provides a remarkably high tumour-to-background contrast in untreated and pretreated glioblastoma and shows tracer uptake even beyond contrast enhancement on MRI. To what extent 18F-GE-180 uptake reflects the tumour extent of humangliomas and inflammatory cells remains to be evaluated in future prospective studies with guided stereotactic biopsies and correlation of histopathological results.
Entities:
Keywords:
18F-GE-180; Glioma; Radiotherapy planning; TSPO PET
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Markus Hutterer; Martha Nowosielski; Daniel Putzer; Nathalie L Jansen; Marcel Seiz; Michael Schocke; Mark McCoy; Georg Göbel; Christian la Fougère; Irene J Virgolini; Eugen Trinka; Andreas H Jacobs; Günther Stockhammer Journal: Neuro Oncol Date: 2013-01-17 Impact factor: 12.300
Authors: J H Mehrkens; G Pöpperl; W Rachinger; J Herms; K Seelos; K Tatsch; J C Tonn; F W Kreth Journal: J Neurooncol Date: 2008-01-23 Impact factor: 4.130
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Alex M Dickens; Susanne Vainio; Päivi Marjamäki; Jarkko Johansson; Paula Lehtiniemi; Johanna Rokka; Juha Rinne; Olof Solin; Merja Haaparanta-Solin; Paul A Jones; William Trigg; Daniel C Anthony; Laura Airas Journal: J Nucl Med Date: 2014-02-10 Impact factor: 10.057
Authors: Roger Stupp; Monika E Hegi; Thierry Gorlia; Sara C Erridge; James Perry; Yong-Kil Hong; Kenneth D Aldape; Benoit Lhermitte; Torsten Pietsch; Danica Grujicic; Joachim Peter Steinbach; Wolfgang Wick; Rafał Tarnawski; Do-Hyun Nam; Peter Hau; Astrid Weyerbrock; Martin J B Taphoorn; Chiung-Chyi Shen; Nalini Rao; László Thurzo; Ulrich Herrlinger; Tejpal Gupta; Rolf-Dieter Kortmann; Krystyna Adamska; Catherine McBain; Alba A Brandes; Joerg Christian Tonn; Oliver Schnell; Thomas Wiegel; Chae-Yong Kim; Louis Burt Nabors; David A Reardon; Martin J van den Bent; Christine Hicking; Andriy Markivskyy; Martin Picard; Michael Weller Journal: Lancet Oncol Date: 2014-08-19 Impact factor: 41.316
Authors: Zhangjie Su; Federico Roncaroli; Pascal F Durrenberger; David J Coope; Konstantina Karabatsou; Rainer Hinz; Gerard Thompson; Federico E Turkheimer; Karolina Janczar; Daniel Du Plessis; Andrew Brodbelt; Alan Jackson; Alexander Gerhard; Karl Herholz Journal: J Nucl Med Date: 2015-02-26 Impact factor: 10.057
Authors: Nathalie L Albert; Marcus Unterrainer; Matthias Brendel; Lena Kaiser; Markus Zweckstetter; Paul Cumming; Peter Bartenstein Journal: Eur J Nucl Med Mol Imaging Date: 2019-03-02 Impact factor: 9.236
Authors: Paolo Zanotti-Fregonara; Mattia Veronese; Belen Pascual; Robert C Rostomily; Federico Turkheimer; Joseph C Masdeu Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-17 Impact factor: 9.236
Authors: M Unterrainer; D F Fleischmann; F Vettermann; V Ruf; L Kaiser; D Nelwan; S Lindner; M Brendel; V Wenter; S Stöcklein; J Herms; V M Milenkovic; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; N L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-05 Impact factor: 9.236
Authors: Julia K Götzl; Matthias Brendel; Georg Werner; Samira Parhizkar; Laura Sebastian Monasor; Gernot Kleinberger; Alessio-Vittorio Colombo; Maximilian Deussing; Matias Wagner; Juliane Winkelmann; Janine Diehl-Schmid; Johannes Levin; Katrin Fellerer; Anika Reifschneider; Sebastian Bultmann; Peter Bartenstein; Axel Rominger; Sabina Tahirovic; Scott T Smith; Charlotte Madore; Oleg Butovsky; Anja Capell; Christian Haass Journal: EMBO Mol Med Date: 2019-06 Impact factor: 12.137
Authors: Marcus Unterrainer; C Mahler; L Vomacka; S Lindner; J Havla; M Brendel; G Böning; B Ertl-Wagner; T Kümpfel; V M Milenkovic; R Rupprecht; M Kerschensteiner; P Bartenstein; Nathalie L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-09 Impact factor: 9.236
Authors: Sujata Sridharan; Joel Raffel; Ashwini Nandoskar; Chris Record; David J Brooks; David Owen; David Sharp; Paolo A Muraro; Roger Gunn; Richard Nicholas Journal: Mol Imaging Biol Date: 2019-10 Impact factor: 3.488
Authors: Bastian Zinnhardt; Michael Müther; Wolfgang Roll; Philipp Backhaus; Astrid Jeibmann; Claudia Foray; Cristina Barca; Christian Döring; Bertrand Tavitian; Frédéric Dollé; Matthias Weckesser; Alexandra Winkeler; Sven Hermann; Stefan Wagner; Heinz Wiendl; Walter Stummer; Andreas H Jacobs; Michael Schäfers; Oliver M Grauer Journal: Neuro Oncol Date: 2020-07-07 Impact factor: 12.300
Authors: Marcus Unterrainer; D F Fleischmann; C Diekmann; L Vomacka; S Lindner; F Vettermann; M Brendel; V Wenter; B Ertl-Wagner; J Herms; C Wetzel; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; Nathalie L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-22 Impact factor: 9.236